Drug Development Pipeline
VX-371 formerly (P-1037)
VX-371 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
A phase two study to test the safety and effectiveness of VX-371 in people with CF who are taking lumacaftor/ivacaftor was conducted in 2017. No further development in CF is planned at this time.
This program is sponsored by Vertex Pharmaceuticals Inc. and Parion Sciences and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent VX-371 formerly (P-1037) Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More